Core Viewpoint - The collaboration between Xianju Pharmaceutical and Hangzhou Aomei Pharmaceutical focuses on the development, production, and commercialization of the drug Aomeikongsu Sodium (also known as Ageng Glucose Sodium Injection) [1][2] Group 1: Agreements and Collaborations - Xianju Pharmaceutical signed multiple agreements with Hangzhou Aomei, including the initial development cooperation agreement in December 2015, a supplementary agreement in April 2021, and a strategic cooperation framework agreement in January 2023 [1] - On January 16, 2026, Xianju Pharmaceutical, Hangzhou Aomei, and Aishijian (Guangdong) Pharmaceutical Co., Ltd. entered into a tripartite agreement to authorize Aishijian as the exclusive marketing service provider for Ageng Glucose Sodium Injection in mainland China [2] - The commercialization milestone sharing agreement and sales revenue sharing agreement stipulate that both Xianju Pharmaceutical and Hangzhou Aomei will share 50% of the commercialization milestones and net sales revenue after deducting relevant expenses [2] Group 2: Product Naming and Regulatory Aspects - The Chinese common name for Aomeikongsu Sodium and its injection form is officially recognized as Ageng Glucose Sodium and Ageng Glucose Sodium Injection, respectively [1] - The agreements outline specific terms regarding the procurement of raw materials and contract manufacturing for Ageng Glucose Sodium Injection [2]

证券代码：002332 证券简称：仙琚制药 公告编号：2026-003 浙江仙琚制药股份有限公司 关于签订共同授权合作产品中国境内推广服务之三方协议 及相关协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"、"仙琚制药"）与杭州奥默医 药股份有限公司（以下简称"杭州奥默"）于2015年12月17日签署了《1.1类新药奥 美克松钠产品开发合作协议》（公告编号：2015-058）、2021年4月16日签署了《1.1 类新药奥美克松钠产品开发合作协议》之补充协议（公告编号：2021-014）、2023年 1月12日签署了《1.1类新药靶向性肌松拮抗剂奥美克松钠产品战略合作框架协议》等 相关协议（"原协议"），就奥美克松钠（阿更葡糖钠注射液）（以下简称"合作产 品"）的研发、生产及商业化合作达成各项约定。 根据国家药典委员会2025年10月《关于申报奥美克松钠产品通用名称的函》："奥 美克松钠"、"奥美克松钠注射液"，中文通用名称为"阿更葡糖钠"、"阿更葡糖 钠注射液"。以下各协议中的"奥美克松钠注射液"均指"阿更葡 ...

Group 1 - The company has announced a partnership with Hangzhou Aomei Pharmaceutical Co., Ltd. to jointly authorize Aishijian (Guangdong) Pharmaceutical Co., Ltd. as the exclusive marketing service provider for Agomelatine injection in mainland China (excluding Hong Kong, Macau, and Taiwan) [1] - A milestone revenue-sharing agreement and sales revenue-sharing agreement have been signed, with both parties agreeing to share commercial revenue equally at 50% [1] - Additionally, a raw material procurement supply agreement and a supplementary contract for commissioned processing production have been established [1]

证券代码：002332 证券简称：仙琚制药 公告编号：2026-002 浙江仙琚制药股份有限公司 关于子公司收到保险赔付的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"）的全资子公司Newchem S.P.A （以下简称"Newchem公司"）近日收到有关《保险赔付确认函》，本次保险赔付确 认函新确认的保险赔付金额为920万欧元（含第三方鉴定费用20万欧元），2025年2月 已收到保险赔款450万欧元，保险公司最终确认的保险赔付金额为1370万欧元。 Newchem 公司位于意大利维罗纳厂区的一处烘箱干燥区域于2024年6月26日发生 意外火灾事故，致该部分区域设备设施损毁，无人员伤亡。受损区域已完成重建并已 经重新投入运行。 该火灾事故发生于2024年6月26日晚上20点左右，车间员工在对烘箱进行清洁时 突然发生起火，火势蔓延到了相邻区域和设备。现场出现火情后，车间员工在第一时 间上报当地消防部门，消防部门和公司应急小组协同完成了灭火工作。火灾造成4台 烘箱及周边部分设备设施损毁，无人员伤亡。 Newchem ...

Core Viewpoint - Newchem S.P.A, a wholly-owned subsidiary of Xianju Pharmaceutical, has received an insurance compensation confirmation letter for a total amount of €9.2 million, which includes €200,000 for third-party assessment fees, following a fire incident at its facility in Verona, Italy [1] Group 1 - The fire incident occurred on June 26, 2024, damaging equipment in the drying area, but there were no casualties reported [1] - The total confirmed insurance compensation amount by the insurance company is €13.7 million, of which €4.5 million was received in February 2025 [1] - The damaged area has been rebuilt and is now back in operation [1] Group 2 - The company received the new insurance compensation payment of €9.2 million on January 13, 2026 [1] - According to preliminary financial confirmations, this compensation is expected to have a certain impact on the company's profits for the fiscal year 2025, with specific effects to be detailed in the annual audit report [1]

Core Viewpoint - The company emphasizes its commitment to innovation and breakthroughs in both raw materials and formulation development, focusing on high-tech areas and clinical needs [1] Group 1: Raw Material Development - The company aims to upgrade processes and achieve breakthroughs in high-tech fields such as sterility and crystal size [1] Group 2: Formulation Innovation - The company plans to initiate projects for modified new drugs and explore innovative targets based on clinical needs and disease mechanisms [1] Group 3: Innovation Process - The company views innovation as a continuous process of experimentation and iteration [1]

Core Viewpoint - The report highlights the growth trends in China's chemical pharmaceutical raw materials industry, indicating a steady increase in production and market dynamics from 2025 to 2032 [1] Industry Summary - In November 2025, China's chemical pharmaceutical raw material production reached 331,000 tons, reflecting a year-on-year growth of 1.5% [1] - From January to November 2025, the cumulative production of chemical pharmaceutical raw materials in China was 3,358,000 tons, with a cumulative growth of 1.8% [1] - The report by Zhiyan Consulting provides insights into the supply and demand dynamics of the chemical pharmaceutical industry in China, projecting future trends from 2026 to 2032 [1] Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1]

Group 1 - Wanhua Chemical's Yantai Industrial Park's ethylene unit has completed a technical upgrade and resumed production, achieving flexible feedstock switching between ethane and propane, enhancing competitiveness in the petrochemical industry [1] - United Water has won a long-term operation contract for municipal wastewater treatment in Saudi Arabia, with an estimated total investment of approximately 378 million RMB over a 15-year cooperation period [2] - Minsheng Health plans to invest 98 million RMB to establish a fund focused on the health industry, contributing 49% of the total fund size of 200 million RMB [3] Group 2 - Jialitu's shareholder, Anle Group, plans to reduce its stake by up to 3% of the company's total shares [4] - Laiyifen's controlling shareholder intends to reduce its stake by no more than 3% of the total shares [5] - Taifu Pump's actual controller's concerted action party plans to reduce its stake by up to 0.535% [7] Group 3 - Vanke A's executive vice president, Yu Liang, has resigned due to retirement [8] - Tian Sheng New Materials has suspended trading due to a potential change in control involving its largest shareholder [10] - Taisun Wind Power is in the early stages of business layout in the commercial aerospace sector [11] Group 4 - Lushin Investment holds only 0.89% equity in Blue Arrow Aerospace, indicating minimal impact on its financial status [12] - Huibo Pu's controlling shareholder is planning a change in control, leading to stock suspension [13] - Tubaobao's subsidiary is selling a stake in Daziran Home and acquiring specific equity for 4 billion RMB [14] Group 5 - Xingchen Technology plans to repurchase shares worth between 60 million and 120 million RMB for employee stock ownership plans [15] - Pulite expects no large-scale orders for its LCP film products in the brain-computer interface sector in the short term [16] - Rijiu Optoelectronics plans to raise up to 800 million RMB through a private placement for a functional film project [17] Group 6 - Yingqu Technology forecasts a net profit increase of 114.69% to 162.4% in 2025, with expected revenue growth of 13% to 18% [19] - Shanda Electric has won a project from Southern Power Grid worth approximately 13.43 million RMB [20] - Changhong Technology's subsidiary has secured over half of a major semiconductor customer's procurement share, amounting to over 10 million RMB [21] Group 7 - Pairui Co. has signed a framework agreement for bulk procurement of IGBT chips, with projected orders totaling approximately 1.74 billion RMB [22] - Aimeike has received a drug registration certificate for its exclusive distribution of injectable botulinum toxin products in China [23] - Quanyin High-Tech's stock will resume trading after a takeover offer from Zhongzhong Group, which now holds 40.51% of the company [24] Group 8 - Hailiang Co. has decided to suspend its investment in Jinlong Group due to significant external changes [25] - Quanxin Co. plans to issue convertible bonds to raise up to 312 million RMB for aviation communication projects [26] - Kangtai Bio's clinical trial application for a combined vaccine has been accepted by the National Medical Products Administration [27] Group 9 - Huaxia Happiness expects to report a net loss for 2025, with losses projected to exceed the previous year's audited net assets [28] - Xianju Pharmaceutical has received a drug registration certificate for Betamethasone Sodium Phosphate Injection [29] - Huaxia Happiness's controlling shareholder is involved in arbitration with a claim amount of approximately 6.4 billion RMB [30] Group 10 - Shaoneng Co. has launched its smart control center project, with an investment of 8.7 million RMB [31] - Jiangshun Technology is planning to establish an investment fund with professional institutions, with details still under discussion [32] - Beifang Changlong intends to acquire 51% of Shunyi Technology, which may constitute a major asset restructuring [33] Group 11 - Guoji Heavy Industry's revenue from "controlled nuclear fusion" products is currently negligible [34] - Hongrun Construction's shareholder plans to reduce its stake by up to 0.12% [35] - Puni Testing expects a net loss of 200 to 250 million RMB for 2025, although this represents an improvement from the previous year's loss [36] Group 12 - Kede Education's controlling shareholder is planning a change in control through a share transfer agreement [38] - Zhongwei Company’s major shareholder plans to reduce its stake by up to 2% [39] - Tongcheng New Materials is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [40] Group 13 - ST Jianyi's shareholder plans to reduce its stake by up to 1.23% [41]

（编辑 丛可心） 证券日报网讯 1月8日，仙琚制药发布公告称，公司近日获国家药监局核准签发倍他米松磷酸钠注射液 《药品注册证书》，规格1ml：4mg（按C₂₂H₂₉FO₅计），属化学药品3类，用于需糖皮质激素治疗疾 病，已视同通过一致性评价，将丰富产品线。 ...

智通财经APP讯，仙琚制药(002332.SZ)公告，公司近日收到国家药品监督管理局核准签发的关于倍他米 松磷酸钠注射液的《药品注册证书》，公司倍他米松磷酸钠注射液被批准注册。倍他米松磷酸钠注射液 主要用于需要使用糖皮质激素治疗的疾病。 ...